0000947871-21-000155.txt : 20210211
0000947871-21-000155.hdr.sgml : 20210211
20210211174637
ACCESSION NUMBER: 0000947871-21-000155
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210210
FILED AS OF DATE: 20210211
DATE AS OF CHANGE: 20210211
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sukhtian Ghiath M.
CENTRAL INDEX KEY: 0001717441
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37759
FILM NUMBER: 21621283
MAIL ADDRESS:
STREET 1: 7TH CIRCLE, ZAHRAN ST.
STREET 2: ZAHRAN PLAZA BUILDING, 4TH FLOOR
CITY: AMMAN
STATE: M2
ZIP: 11844
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GMS Ventures & Investments
CENTRAL INDEX KEY: 0001804598
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37759
FILM NUMBER: 21621284
BUSINESS ADDRESS:
STREET 1: C/O INTERTRUST CORP. SVCS. (CAYMAN) LTD.
STREET 2: 190 ELGIN AVENUE
CITY: GEORGE TOWN
STATE: E9
ZIP: KYI-9007
BUSINESS PHONE: 962 6 582 7999
MAIL ADDRESS:
STREET 1: C/O INTERTRUST CORP. SVCS. (CAYMAN) LTD.
STREET 2: 190 ELGIN AVENUE
CITY: GEORGE TOWN
STATE: E9
ZIP: KYI-9007
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Outlook Therapeutics, Inc.
CENTRAL INDEX KEY: 0001649989
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 383982704
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0930
BUSINESS ADDRESS:
STREET 1: 4260 U.S. ROUTE 1
CITY: MONMOUTH JUNCTION
STATE: NJ
ZIP: 08852
BUSINESS PHONE: 6096193990
MAIL ADDRESS:
STREET 1: 4260 U.S. ROUTE 1
CITY: MONMOUTH JUNCTION
STATE: NJ
ZIP: 08852
FORMER COMPANY:
FORMER CONFORMED NAME: Oncobiologics, Inc.
DATE OF NAME CHANGE: 20150804
4
1
ownership.xml
X0306
4
2021-02-10
0
0001649989
Outlook Therapeutics, Inc.
OTLK
0001717441
Sukhtian Ghiath M.
7TH CIRCLE, ZAHRAN ST.
ZAHRAN PLAZA BLDG, 4TH FLOOR
AMMAN
M2
11844
JORDAN
1
0
1
0
0001804598
GMS Ventures & Investments
C/O INTERTRUST CORP. SVCS. (CAYMAN) LTD.
190 ELGIN AVENUE
GEORGE TOWN
E9
KYI-9007
CAYMAN ISLANDS
1
0
0
0
Common Stock
2021-02-10
4
A
0
1013627
1
A
11834257
I
See Footnotes
Common Stock
50965058
I
See Footnotes
These securities are held of record by GMS Ventures and Investments ("GMS Ventures"). Ghiath M. Sukhtian ("Ghiath Sukhtian"), a natural person, is the holder of a controlling interest in GMS Ventures. GMS Ventures has designated one representative to serve on the Issuer's board of directors. Therefore, GMS Ventures and Ghiath Sukhtian may be deemed a director by deputization.
By virtue of the relationships described above in Footnote 1, Ghiath Sukhtian may be deemed to have voting and investment power with respect to the securities held by GMS Ventures noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Reporting Persons disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
These securities are held of record by BioLexis Pte Ltd. ("BioLexis"). Tenshi Life Sciences Private Limited ("Tenshi"), a private investment vehicle controlled by Arun Kumar Pillai ("Kumar"), and GMS Pharma (Singapore) Pte. Limited ("GMS Pharma"), a private investment company and wholly-owned subsidiary of GMS Holdings, are the 50:50 beneficial owners of BioLexis, in which each of Tenshi and GMS Pharma owns 50% of the outstanding voting shares. Kumar, a natural person, is the holder of a controlling interest in Tenshi. Ghiath Sukhtian is the holder of a controlling interest in GMS Holdings, which is the holder of a controlling interest in GMS Pharma. The previously filed Form 4 reported an incorrect number of securities indirectly held by BioLexis in column 5, and has been corrected on this Form 4.
By virtue of the relationships described above in Footnote 3, Ghiath Sukhtian may be deemed to have voting and investment power with respect to the securities held by BioLexis noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. Ghiath Sukhtian disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of his pecuniary interest therein, if any. BioLexis has designated four representatives to serve on the Issuer's board of directors. This report shall not be deemed an admission that Ghiath Sukhtian is the beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
/s/ Ghiath M. Sukhtian, By: Lawrence Kenyon, Attorney-in-Fact
2021-02-11
/s/ GMS Ventures and Investments, By: Lawrence Kenyon, Attorney-in-Fact
2021-02-11